CDER May Form New Office Of Drug Evaluation For CBER Reviewers
Executive Summary
The Center for Drug Evaluation & Research is considering creating a sixth Office of Drug Evaluation to incorporate the CBER review divisions that are transferring to the drug center
You may also be interested in...
FDA Nominee Is Crawford: Choice Emphasizes Continuity, Cooperation
The Bush Administration's announcement that it intends to nominate Lester Crawford to be permanent FDA commissioner means that the pharmaceutical industry can count on continuity heading into the renewal process for the prescription drug user fee program
FDA Nominee Is Crawford: Choice Emphasizes Continuity, Cooperation
The Bush Administration's announcement that it intends to nominate Lester Crawford to be permanent FDA commissioner means that the pharmaceutical industry can count on continuity heading into the renewal process for the prescription drug user fee program
CBER/CDER Consolidation: Weiss Named Acting Director Of New ODE VI
CBER Office of Therapeutics Research & Review Acting Director Sharon Risso will continue to serve as the point person for biologics staff transition questions after the consolidation with FDA's drugs center